FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Sarantopoulos

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Anatomy

Livers

Phenomena

Metabolic Clearance Rate

Co-author Network

Publications

TOP 3
Monica Mita; E Poplin; V M Rivera; E H Rubin; John Sarantopoulos; B B Scott; W D Tap; L Berk; C D Britten; P Dodion; F Haluska; J W Loewy; A Mita; A Tolcher
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
Jan Drappatz; April Eichler; Kelly Elian; Robert M Fielding; Morris D Groves; Stephen Kelsey; Betty Lawrence; Christina A Meyers; Tom Mikkelsen; Steve Rosenfeld; John Sarantopoulos; David Schiff; Mona Shing; Xiaolin Wang; Andrew Brenner; Jean Paul Castaigne; Eric T Wong; Patrick Y Wen
Phase I study of GRN1005 in recurrent malignant glioma.
John Nemunaitis; Swami Padmanabhan-Iyer; John Sarantopoulos; Joe Stephenson; Lyon Gleich; Alain Mita; Monica M Mita; Nisha Nanda; Annie-Claude Benichou; Adam Craig
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Sarantopoulos (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Monica Mita; E Poplin; V M Rivera; E H Rubin; John Sarantopoulos; B B Scott; W D Tap; L Berk; C D Britten; P Dodion; F Haluska; J W Loewy; A Mita; A Tolcher
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(4):1104-11.
2013: Jan Drappatz; April Eichler; Kelly Elian; Robert M Fielding; Morris D Groves; Stephen Kelsey; Betty Lawrence; Christina A Meyers; Tom Mikkelsen; Steve Rosenfeld; John Sarantopoulos; David Schiff; Mona Shing; Xiaolin Wang; Andrew Brenner; Jean Paul Castaigne; Eric T Wong; Patrick Y Wen
Phase I study of GRN1005 in recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(6):1567-76.
2013: John Nemunaitis; Swami Padmanabhan-Iyer; John Sarantopoulos; Joe Stephenson; Lyon Gleich; Alain Mita; Monica M Mita; Nisha Nanda; Annie-Claude Benichou; Adam Craig
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Cancer chemotherapy and pharmacology 2013;71(1):35-41.
2012: Lee S Rosen; Poornima Shubhakar; Min Zhu; Emily Chan; Hongjie Deng; Gregory Friberg; Jill Gilbert; Yuying C Hwang; Deva Mahalingam; Ian McCaffery; Shaunita A Michael; Alain C Mita; Monica M Mita; Marilyn Mulay; Igor Puzanov; John Sarantopoulos
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(12):3414-27.
2012: Patricia M LoRusso; Sridhar Mani; Daniel Mulkerin; Rachel Neuwirth; Ramesh K Ramanathan; Michelle A Rudek; John Sarantopoulos; Stephen I Shibata; Chris H Takimoto; Karthik Venkatakrishnan; Afshin Dowlati; Dixie Esseltine; Anne Hamilton; Percy Ivy
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(10):2954-63.
2012: Razelle Kurzrock; Alain Mita; Stacy Moulder; Kamalesh Sankhala; Danielle Bouchard; Andrew Brenner; Chandtip Chandhasin; Kelly Elian; Nash Gabrail; Carrie Smith; John Sarantopoulos
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Molecular cancer therapeutics 2012;11(2):308-16.
2011: Ronan T Swords; David J Bearss; Jennifer Carew; Kevin Robert Kelly; Deva Mahalingam; Steffan Nawrocki; John Sarantopoulos; Francis Giles
The Pim kinases: new targets for drug development.
Current drug targets 2011;12(14):2059-66.
2011: Muhammad Wasif Saif; John Sarantopoulos; Chris H Takimoto; Anthony W Tolcher; Amita Patnaik; Muralidhar Beeram
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2011;68(6):1565-73.
2011: Ticiana B Leal; Heinz-Josef Lenz; Patricia M LoRusso; Sridhar Mani; James Mier; Angela Davies; Merrill J Egorin; Anne Hamilton; S Percy Ivy; Rachel Neuwirth; Ramesh K Ramanathan; Scot C Remick; John Sarantopoulos; Stephen Shibata; Chris H Takimoto; Karthik Venkatakrishnan; Lisa von Moltke; John J Wright; Daniel Mulkerin
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Cancer chemotherapy and pharmacology 2011;68(6):1439-47.
2011: Alejandro D Ricart; Kale E Ruby; John Sarantopoulos; Anthony W Tolcher; Angela Zambito; Edward A Ashton; Joanna M Brell; Matthew M Cooney; Maria A Feldman; Kazuko Matsuda; Gerardo Medina; Mark S Munsey; Scot C Remick
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2011;68(4):959-70.
2010: Suresh S Ramalingam; Shivaani Kummar; John Sarantopoulos; Stephen Shibata; Patricia M LoRusso; Mara Yerk; Julianne Holleran; Yan Lin; Jan H Beumer; R Donald Harvey; S Percy Ivy; Chandra P Belani; Merrill J Egorin
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):4507-12.
2010: Catalin Mita; Chris H Takimoto; Monica Mita; Anthony Tolcher; Kamalesh Sankhala; John Sarantopoulos; Manuel Valdivieso; Leslie Wood; Erik Rasmussen; Yu-Nien Sun; Z Don Zhong; Michael B Bass; NgocDiep Le; Patricia M LoRusso
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(11):3044-56.
2010: Saby George; Andrew Brenner; John Sarantopoulos; Ronald M Bukowski
RANK ligand: effects of inhibition.
Current oncology reports 2010;12(2):80-6.
2009: Kamalesh K Sankhala; Devesh M Pandya; John Sarantopoulos; Scott A Soefje; Francis Giles; Sant P Chawla
Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Expert opinion on drug metabolism & toxicology 2009;5(12):1607-14.
2009: Anthony W Tolcher; John Sarantopoulos; Amita Patnaik; Kyriakos Papadopoulos; Chia-Chi Lin; Jordi Rodon; Barbara Murphy; Bruce Roth; Ian McCaffery; Kevin Gorski; Brianne Kaiser; Min Zhu; Hongjie Deng; Greg Friberg; Igor Puzanov
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5800-7.
2009: Monica Mita; Catalin Mita; John Sarantopoulos; Chris H Takimoto; Eric K Rowinsky; Ofelia Romero; Patrizia Angiuli; Cecilia Allievi; Amy Eisenfeld; Claire F Verschraegen
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2009;64(2):287-95.
2009: Alejandro D Ricart; John Sarantopoulos; Emiliano Calvo; Quincy S Chu; Douglas Greene; Faith E Nathan; Michael E Petrone; Anthony W Tolcher; Kyriakos P Papadopoulos
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3866-71.
2009: Chia-Chi Lin; Emiliano Calvo; Kyriakos P Papadopoulos; Amita Patnaik; John Sarantopoulos; Catalin Mita; Glenn G Preston; Monica Mita; Jordi Rodon; Theresa Mays; I-Tien Yeh; Pat O'Rourke; Chris H Takimoto; Janet E Dancey; Helen Chen; Anthony W Tolcher
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2009;63(6):1065-71.
2008: Kyriakos P Papadopoulos; SANJAY GOEL; Muralidhar Beeram; Alvin Wong; Kavita Desai; Missak Haigentz; María L Milián; Sridhar Mani; Anthony W Tolcher; Alshad S Lalani; John Sarantopoulos
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7110-5.
1997: Michael P Czubryt; J C Russell; John Sarantopoulos; James S C Gilchrist; Grant N Pierce
Age- and sex-related differences in nuclear lipid content and nucleoside triphosphatase activity in the JCR:LA-cp corpulent rat.
Molecular and cellular biochemistry 1997;176(1-2):327-35.
1996: Michael P Czubryt; J C Russell; John Sarantopoulos; Grant N Pierce
Nuclear cholesterol content and nucleoside triphosphatase activity are altered in the JCR:LA-cp corpulent rat.
Journal of cellular biochemistry 1996;63(3):349-57.